Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03220165 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196
A Phase 1 study, sponsored by Madrigal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03220165: Completed Phase 1 study, sponsored by Madrigal Pharmaceuticals.
NCT03220165 is a Phase 1 study that has completed, run by Madrigal Pharmaceuticals. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03220165, a Phase 1 study, has completed, sponsored by Madrigal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is determine in healthy males how MGL-3196 is metabolized using a radio-labeled version of MGL-3196.
Primary Outcome
Measurement of the total radioactivity collected from blood, urine, and feces
Interventions
- DRUG MGL-3196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-08-06 |
| Est. Completion | 2017-09-03 |
| Phase | Phase 1 |
What the finished NCT03220165 record still lists
NCT03220165 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which MGL-3196 is the first listed.
NCT03220165 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03220165 about?
NCT03220165 is a clinical study titled "Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196". The purpose of this study is determine in healthy males how MGL-3196 is metabolized using a radio-labeled version of MGL-3196.
What is the current status of trial NCT03220165?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2017-08-06. Estimated completion is 2017-09-03.
What interventions are being tested in trial NCT03220165?
The interventions under investigation include: MGL-3196 (DRUG).
Who is sponsoring clinical trial NCT03220165?
This trial is sponsored by Madrigal Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03220165's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI